“Prostate cancer patients treated with Cesium-131 brachytherapy maintained their urinary- and bowel-related quality of life years afterward, according to a recent study.”

The study, “Long-term Quality of Life in Prostate Cancer Patients Treated with Cesium-131,” was published in the Journal of Radiation Oncology, Biology, Physics and was recently featured by Prostate Cancer News Today contributor Daniela Semedo.

Daniela writes:

“The main goal of the study was to evaluate urinary and bowel side effects stemming from the brachytherapy treatment. A median of 5 1/2 years after brachytherapy, patients reported no significant changes in their EPIC or AUA scores.

“Overall, the study showed that there were minimal long-term changes in patients’ urinary and bowel quality of life after brachytherapy.

“The findings suggest that men treated with this form of radiotherapy can recover and maintain their pre-treatment quality of life long term, the researchers said.”

“This study reinforces the position of Cesium 131 as an effective, patient-friendly treatment for localized prostate cancer,” says Isoray Chief Scientific Officer Bill Cavanagh. “This is especially important as multiple studies are emerging that strongly suggest that the inclusion of brachytherapy must be considered for the treatment of high-risk prostate cancer – the toughest localized prostate cancer to cure.”

“We have previously reported that Cesium-131 leads to quicker recovery of voiding function, with return to clinical baseline by 3 months and statistical baseline by 6 months post-treatment,” said Ron Benoit, a urologist who was the study author. “Our current findings strengthen this body of literature by demonstrating that patients treated with the Cesium-131 isotope are able to maintain this baseline quality of life in the long term.”

You can click here to read the full article from Prostate Cancer News Today.

If you would like to learn more about how brachytherapy may improve outcomes for many types of cancer patients, contact info@isoray.com.